[media releases] [press release]legochem biosciences enters licensing agreement with rmx biopharma for lcb01-0371 (gram-positive antibiotic) regarding china market

legochem biosciences enters licensing agreement with rmx biopharma for lcb01-0371 (gram-positive antibiotic) regarding china market.

- daejeon, december 12, 2016 -

legochem biosciences. (headquarter: daejeon south korea, hereinafter “lcb”) announced today that rmx biopharma (head office: shanghai china, hereinafter 'rmx'）and lcb have entered into a license agreement for the development, manufacture, and commercialization of lcb01-0371(next generation oxazolidinone antibiotic) in china.

under the agreement, rmx exclusively obtains rights and license to develop, manufacture and commercialize lcb01-0371 in china. in consideration of the license granted to rmx, lcb will receive an initial upfront payment and following development, regulatory and sales milestone payments as well as royalties.

lcb01-0371 is a next generation oxazolidinone antibiotic which had shown efficacy & long term safety over various gram-positive super-bacteria including mrsa, vre, mdr-tb through preclinical & early clinical trial studies.

china is recognized as a leading growth market for antibiotics in terms of antibiotic consumption it is already world second largest market and tuberculosis is one of china's major public health problems. according to the 2015 who estimates, china has the world's largest number of multi drug resistant tuberculosis cases out of newly diagnosed tb cases.

rmx plans to develop lcb01-0371 as an antibiotic to treat various types of gram-positive super-bacteria including mrsa, vre and mdr-tb.

dr. yong zu kim. ceo & president of lcb said “license agreement with rmx is a milestone for our company and a significant opportunity for us to access chinese market. rmx represents a strong strategic partner with expertise in drug development & commercialization. in addition to its planned development in china lcb is committed to advancing currently on-going clinical trials in korea and discussing additional license out opportunities with global biopharmaceutical companies.”

dr. ruiping dong, chairman & ceo of rmx has commented, “we plan to address significant unmet medical needs in china through providing solutions for patients in desperate need of next generation antibiotics by accordingly developing lcb01-0371. we believe development of lcb01-0371 will also advance our position in the anti-infectious diseases within china.”

about legochem biosciences, inc.

legochem biosciences is a biopharmaceutical company focusing on the development of next generation novel therapeutics utilizing its proprietary medicinal drug discovery technology ‘legochemistry^tm’ & adc platform technology ‘conjuall^tm’.

since its foundation in 2006 lcb has focused on the research and development of adc (antibody-drug conjugate), anti-biotics, anti-coagulants & anti-cancer therapeutics based on proprietary platform technologies.

in jul. 2016, legochem biosciences have established jv geom therapeutics with us antibiotic experts to globally develop & commercialize its cephalosporin antibiotic and also in aug. 2015, signed a license and commercialization agreement with fosun pharma regarding her2 targeting adc for the greater china market.

about rmx biopharma

rmx biopharm is a clinical stage biotech company focusing innovative drug development in infectious diseases, oncology, cns/pain areas with highly unmet medical needs for china and north asia, including china, japan, and korea.